Recruiting Trials
Recruiting Trials are clinical trials that are fully approved and accepting patients. Please click on the links below for further information about trials currently accepting patients.
01.10 CARPETS
02.12 RADICAL
01.15 CHARLI
04.17 SMARTI
09.17 PRIME002
10.17 GoTHAM
02.18 MelMarT-II
03.18 I-MAT
02.19 IMAGE
01.10 CARPETS
Phase I study of safety and immune effects of an escalating dose of autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells in patients with metastatic melanoma
Chair
Professor Michael Brown
Registration ID
Trial Status
Recruiting Trial
MASC Trials Contact
02.12 RADICAL
A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna when staged surgical excision with 5mm margins is not possible, is refused, or fails
Chair
Associate Professor Pascale Guitera
Registration ID
Trial Status
Recruiting Trial
MASC Trials Contact
01.15 CHARLI
A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients with Unresectable Stage III and IV Melanoma
Chair
Associate Professor Shahneen Sandhu
Registration ID
Trial Status
Recruiting Trial
MASC Trials Contact
04.17 SMARTI
A Pilot Study of an Artificial Intelligence System as a Diagnostic Aide for Better Skin Cancer Management
Chair
Associate Professor Victoria Mar
Registration ID
Trial Status
Recruiting Trial
MASC Trials Contact
09.17 PRIME002
Early Phase II Study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Chair
Dr Andre van der Westhuizen
Registration ID
Trial Status
Recruiting Trial
MASC Trials Contact
10.17 GoTHAM
A Phase Ib/II study of combination avelumab with peptide receptor radionuclide therapy or conventional fractioned radiotherapy in patients with metastatic Merkel cell carcinoma
Chair
Associate Professor Shahneen Sandhu
Registration ID
Trial Status
Recruiting Trial
MASC Trials Contact
02.18 MelMarT-II
A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma
Chair
Professor Michael Henderson and Professor Marc Moncrieff
Registration ID
Trial Status
Recruiting Trial
MASC Trials Contact
03.18 I-MAT
A randomised, placebo-controlled, Phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma
Chair
Dr Wen Xu
Registration ID
Trial Status
Recruiting Trial
MASC Trials Contact
Further information
To learn more about the I-MAT clinical trial, which aims to improve the management of early stage Merkel Cell Carcinoma, click here. This discussion between Dr Wen Xu (Study Chair), Professor Gerald Fogarty (Chair of AMIGOs) and Jonathan Pincus (Merkel Cell Carcinoma Patient) highlights just why this trial is so vital.
02.19 IMAGE
Melanoma Surveillance Photography to improve early detection of melanoma in very high risk (or high risk) patients
Chair
Associate Professor Victoria Mar
Registration ID
Trial Status
Recruiting Trial
MASC Trials Contact